Bangkok – AstraZeneca (Thailand) Company Limited, in partnership with BNH Hospital (BNH), has inked a collaborative framework aimed at establishing an unparalleled network of excellence in comprehensive asthma care. This alliance, dedicated to enhancing the quality of life for Thai children and safeguarding them against RSV, underscores a commitment to multidisciplinary care of the highest calibre. Termed “Collaborative Excellence in Multidisciplinary Care Network for RSV and Asthma”, this initiative is poised to advance knowledge and understanding surrounding RSV and asthma, supported by a dedicated team of seasoned medical professionals. Furthermore, AstraZeneca remains steadfast in its dedication to personnel development and knowledge exchange through research collaboration, facilitating the introduction of innovative solutions such as “Immunisation against the RSV”, mitigating infection risks, and “Precise Severe Asthma Care”, thus raising respiratory healthcare standards to global benchmarks.
Mr. Roman Ramos, President of AstraZeneca Thailand and Frontier Markets, reveals that RSV infection and asthma represent significant health challenges when left untreated. AstraZeneca (Thailand) Company Limited and BNH Hospital are united in our commitment to combat these conditions through collaboration on “Collaborative Excellence in Multidisciplinary Care Network for RSV and Asthma”. Our shared goal is to enhance the well-being of Thai children, safeguarding them against RSV while fostering a multidisciplinary approach to care. Moreover, this partnership paves the way for groundbreaking innovations such as “Precise Severe Asthma Care” and “Immunisation against the RSV”, aimed at reducing the risk of severe RSV infection among high-risk children during their critical first two years of life.
The primary aim of this collaborative framework is to foster a comprehensive understanding of respiratory health. Beginning with the implementation of treatment protocols and disease prevention strategies, this focus extends to ensuring meticulous attention and support from the initial counselling session onward, reflecting the commitment to achieving optimal patient outcomes. Central to this approach is the establishment of a patient-centric, multidisciplinary care model, prioritising individualised and precise treatment strategies. This entails the establishment of a well-structured referral network alongside initiatives aimed at enhancing personnel expertise, facilitating knowledge exchange through various research channels, and disseminating accurate disease and treatment information to patients of all ages, as well as caregivers of young children.
Dr. Nopparat Panthongwiriyakul, Hospital Director of BNH Hospital states this initiative of “Collaborative Excellence in Multidisciplinary Care Network for RSV and Asthma”, underscores our unwavering dedication to enhancing the quality of life for Thai children, safeguarding them against RSV . Our primary focus lies in cultivating a culture of excellence, aimed at delivering comprehensive care for asthma patients through a seasoned multidisciplinary team with specialised expertise in managing respiratory diseases. Notably, lower respiratory tract infections attributed to the RSV stand as the foremost cause of hospitalisations among infants in their first year of life, particularly during peak seasons typically starting from June to October, coinciding with the rainy season. The correlation between RSV infection during infancy and the subsequent onset of childhood asthma underscores the critical importance of early intervention. Our efforts are strategically aimed at mitigating this risk, as evidenced by the marked reduction in asthma prevalence among children who evade RSV infection in their first year. Thus, our emphasis on proactive disease management remains paramount.
In this collaborative framework, BNH Hospital and AstraZeneca (Thailand) Company Limited plan to provide care for patients of all ages with comprehensive services and medical expertise, particularly in maternal and child health care. Additionally, the integration of new innovations in the treatment of severe asthma through individualised assessment ensures more accurate treatment for each patient. This collaboration also emphasises working as a team to provide multidisciplinary care, ensuring readiness to offer comprehensive and direct treatment
About AstraZeneca
AstraZeneca (Securities abbreviation, AZN on LSE/STO/Nasdaq stock exchanges) is a leading global biopharmaceutical company focusing on discovering, developing, and distributing medicines for medicinal purposes, particularly the group of drugs among cancer, heart disease, kidney, metabolic system, and respiratory disease. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and has millions of patients worldwide benefiting from its innovative medicines. For more information, please visit astrazeneca.com and follow the company on facebook.com/AstraZeneca.TH
For additional media information, please contact:
Cataliya Chalermvongsenee
Public Affairs and Communications Manager
Email: cataliya.chalermvongsenee@astrazeneca.com
Call: +66 (0) 80 064 8217
TH-18339
Expiry date: 13 May 2026